Cargando…

SPOP promotes cervical cancer progression by inducing the movement of PD-1 away from PD-L1 in spatial localization

BACKGROUND: Metastasis is a major obstacle in the treatment of cervical cancer (CC), and SPOP-mediated regulatory effects are involved in metastasis. However, the mechanisms have not been fully elucidated. METHODS: Proteomic sequencing and SPOP immunohistochemistry (IHC) were performed for the pelvi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jiangchun, Wu, Yong, Guo, Qinhao, chen, Siyu, Wang, Simin, Wu, Xiaohua, Zhu, Jun, Ju, Xingzhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429754/ https://www.ncbi.nlm.nih.gov/pubmed/36042498 http://dx.doi.org/10.1186/s12967-022-03574-6

Ejemplares similares

Developing a nomogram for preoperative prediction of cervical cancer lymph node metastasis by multiplex immunofluorescence
por: Wu, Jiangchun, et al.
Publicado: (2023)

RNA-binding proteins in ovarian cancer: a novel avenue of their roles in diagnosis and treatment
por: Wu, Jiangchun, et al.
Publicado: (2022)

Effect of the Number of Removed Lymph Nodes on Survival in Patients with FIGO Stage IB-IIA Cervical Squamous Cell Carcinoma following Open Radical Hysterectomy with Pelvic Lymphadenectomy: A Retrospective Cohort Study
por: Guo, Qinhao, et al.
Publicado: (2021)

Comparison of different lymph node staging systems in patients with node-positive cervical squamous cell carcinoma following radical surgery
por: Guo, Qinhao, et al.
Publicado: (2020)

ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer
por: Tang, Zhe, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

Validation of the prognostic value of various lymph node staging systems for cervical squamous cell carcinoma following radical surgery: a single-center analysis of 3,732 patients
por: Guo, Qinhao, et al.
Publicado: (2020)

Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3(SPOP) to control cancer immune surveillance
por: Zhang, Jinfang, et al.
Publicado: (2017)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

A risk model of gene signatures for predicting platinum response and survival in ovarian cancer
por: Chen, Siyu, et al.
Publicado: (2022)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer
por: Hakozaki, Taiki
Publicado: (2023)

PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
por: Li, Jun, et al.
Publicado: (2022)

SPOP the mutation
por: Rider, Leah, et al.
Publicado: (2015)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

The RNA-Binding Protein CELF2 Inhibits Ovarian Cancer Progression by Stabilizing FAM198B
por: Guo, Qinhao, et al.
Publicado: (2020)

HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway
por: Wu, Yong, et al.
Publicado: (2021)

PD-1/PD-L1 Correlates With the Efficacy of the Treatment of Concurrent Chemoradiotherapy in Cervical Cancer
por: Zhang, Hanqun, et al.
Publicado: (2022)

c‐Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR‐145‐5p/SPOP/PD‐L1 axis
por: Zhang, Lan, et al.
Publicado: (2021)

CUL3/SPOP complex prevents immune escape and enhances chemotherapy sensitivity of ovarian cancer cells through degradation of PD-L1 protein
por: Dong, Min, et al.
Publicado: (2022)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer
por: Wang, Yu-meng, et al.
Publicado: (2022)

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
por: de Jong, Florus C., et al.
Publicado: (2021)

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
por: Yi, Ming, et al.
Publicado: (2018)

KLF5 Promotes Tumor Progression and Parp Inhibitor Resistance in Ovarian Cancer
por: Wu, Yong, et al.
Publicado: (2023)

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
por: Niu, Mengke, et al.
Publicado: (2021)

Analysis of the Role and Mechanism of ZEB1 in Regulating Cervical Carcinoma Progression via Modulating PD-1/PD-L1 Checkpoint
por: Lin, Yuhong, et al.
Publicado: (2022)

SPOP suppresses prostate cancer through regulation of CYCLIN E1 stability
por: Ju, Lin-Gao, et al.
Publicado: (2018)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma
por: Ma, Ke, et al.
Publicado: (2017)

PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed
por: Huang, Weijia, et al.
Publicado: (2022)

Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
por: Wu, Si-Pei, et al.
Publicado: (2015)

PD-L1, Mismatch Repair Protein, and NTRK Immunohistochemical Expression in Cervical Small Cell Neuroendocrine Carcinoma
por: Chen, Longyun, et al.
Publicado: (2021)

Immune profiling reveals prognostic genes in high-grade serous ovarian cancer
por: Wu, Yong, et al.
Publicado: (2020)

SPOP suppresses pancreatic cancer progression by promoting the degradation of NANOG
por: Tan, Peng, et al.
Publicado: (2019)

Retracted: Analysis of the Role and Mechanism of ZEB1 in Regulating Cervical Carcinoma Progression via Modulating PD-1/PD-L1 Checkpoint
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China
por: Liu, Si-Yang, et al.
Publicado: (2017)

PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
por: Rotman, Jossie, et al.
Publicado: (2020)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9rc9kaqj64ejcsdecc74jpp2ja